Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 18/20 | 0.51 |
| ▸ | RARB | P10826 | 19/20 | 0.50 |
| ▸ | RARG | P13631 | 19/20 | 0.50 |
| ▸ | RXRA | P19793 | 4/20 | 0.50 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.50 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6813842 | 1.00 | RARA (0.51) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6814451 | 0.89 | PTPN1 (0.42) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6814443 | 0.89 | PTPN1 (0.42) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6813834 | 0.84 | RXRA (0.49) | RARARARBRARGRXRACYP26A1 | |
| SCHEMBL8028156 | 0.81 | RARA (0.60) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6813827 | 0.80 | RARA (0.74) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6813830 | 0.80 | RARA (0.74) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6814439 | 0.73 | RARB (0.37) | RARARARBRARGRXRACYP26A1 | |
| SCHEMBL8026328 | 0.72 | RARA (0.72) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL7046911 | 0.71 | RARA (0.56) | RARARARBRARGRXRANR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230042181-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-02-09 | — | — | US | disclosed |
| US-11447831-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists | SYROS PHARMACEUTICALS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210285059-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | SYROS PHARMACEUTICALS, INC. | 2021-09-16 | — | — | US | disclosed |
| US-11053552-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists | SYROS PHARMACEUTICALS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200392583-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2020-12-17 | — | — | US | disclosed |
| US-10697025-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists | SYROS PHARMACEUTICALS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190249259-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2019-08-15 | — | — | US | disclosed |
| US-10240210-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists | SYROS PHARMACEUTICALS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180187271-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-07-05 | — | — | US | disclosed |
| US-20180187271-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-07-05 | — | — | US | disclosed |
| US-9868994-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists | SYROS PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868994-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists | SYROS PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9845508-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists | SYROS PHARMACEUTICALS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9845508-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists | SYROS PHARMACEUTICALS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170292165-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-10-12 | — | — | US | disclosed |
| US-20170292165-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-10-12 | — | — | US | disclosed |
| US-20160355888-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-12-08 | — | — | US | disclosed |
| US-20160355888-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-12-08 | — | — | US | disclosed |
| EP-1115687-B1 | 5,6-DIHYDRONAPHTHALENYL DERIVATIVES HAVING RETINOID-LIKE ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6194601-B1 | USEFUL IN TREATMENT OF SKIN DISORDERS SUCH AS ACNE AND DAMAGE FROM AGE OR IRRADIATION; CHRONIC SKIN INFLAMMATORY INFLAMMATORY DISEASES SUCH AS PSORIASIS AND ATOPIC DERMATITIS; ANTITUMOR AGENTS FOR BREAST CANCER, LUNG CANCER; NONTOXIC | BRISTOL-MYERS SQUIBB COMPANY | 2001-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210285059-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | RARA, RARG, RARB | RARA 1/4885RARB 3/4885RARG 2/4885 |
| US-20180187271-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | RARA, RARG, RARB | RARA 1/4885RARB 3/4885RARG 2/4885 |
| US-10240210-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists | RARA, RARG, RARB | RARA 1/4885RARB 3/4885RARG 2/4885 |
| US-10697025-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists | RARA, RARG, RARB | RARA 1/4885RARB 3/4885RARG 2/4885 |
| US-20200392583-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | RARA, RARG, RARB | RARA 1/4885RARB 3/4885RARG 2/4885 |
| US-20190249259-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | RARA, RARG, RARB | RARA 1/4885RARB 3/4885RARG 2/4885 |
| US-11053552-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists | RARA, RARB, RARG | RARA 1/4885RARB 2/4885RARG 3/4885 |
| US-20160355888-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | RARA, RARG, RARB | RARA 1/4885RARB 3/4885RARG 2/4885 |
| US-11447831-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists | RARA, RARG, RARB | RARA 1/4885RARB 3/4885RARG 2/4885 |
| US-20170292165-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | RARA, RARG, RARB | RARA 1/4885RARB 3/4885RARG 2/4885 |
| US-20230042181-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | RARA, RARG, RARB | RARA 1/4885RARB 3/4885RARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.